Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial of the Company's potent and selective menin inhibitor, ziftomenib, including significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The updated clinical data are being featured during a late-breaking oral session at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany. KMT2A-rearrangements are less frequent, representing approximately 5-10% of AML.

No FDA-approved therapies targeting NPM1-mutant and KMT2A-re arranged AML currently exist. Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLLprotein complex and exhibits downstream effects on HXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML.

Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML.